The largest open drug market in Africa, Ọgbọ Ọgwụ, alongside adjoining markets, has come under renewed scrutiny as federal agencies intensify efforts to combat the sale of counterfeit and controlled drugs. A recent intervention at the market revealed alarming discoveries, prompting regulatory authorities to take decisive action.
During a visit to the market, it was observed that other neighboring markets, including the Plumbing Materials Market, had also been shut down. Contrary to political speculations, the leadership of the Plumbing Materials Market confirmed that regulators uncovered disturbing quantities of counterfeit and banned drugs within several shops in their market. These findings raised serious concerns about the infiltration of prohibited pharmaceuticals into the country.
The presence of globally banned drugs in local markets raises critical questions about the supply chain and regulatory oversight. Despite international and local prohibitions, these counterfeit medicines are still being manufactured in India, making their way through Nigerian ports and ultimately reaching consumers. Authorities are now under pressure to tighten import regulations and strengthen surveillance at entry points.
In response to the crisis, the state government has ordered an expedited investigation, aiming to complete the search within ten days. Efforts are also being made to ensure that law-abiding traders at the Plumbing Materials Market can resume operations promptly.
As part of broader reforms, the Anambra State Government is advancing the construction of a coordinated wholesale drug center in Oba, Idemili South LGA. This facility is expected to accommodate the new and standardized Ọgbọ Ọgwụ market, replacing the current unregulated structure where counterfeit drugs proliferate.
Onitsha remains the largest trading hub in Africa, and efforts are underway to elevate its status through regulatory compliance and market modernization. Authorities have reaffirmed their commitment to fostering a safer commercial environment, ensuring that only genuine and approved pharmaceuticals are available in the market.
May Anambra continue to progress in its fight against counterfeit drugs and trade malpractices.
